We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Builds Scalable Data-Driven Personalized Care Platform
Read MoreHide Full Article
Key Takeaways
Hims & Hers integrates EMRs, telehealth and lab testing to create feedback loops for personalized care.
HIMS launched multi-cancer early detection testing to expand screening signals across many conditions.
Hims & Hers is using partnerships, acquisitions and global expansion to grow data and refine care pathways.
Hims & Hers Health, Inc. (HIMS - Free Report) has increasingly positioned itself at the intersection of healthcare and data, building a platform where insights derived from continuous monitoring, diagnostics and user engagement inform care delivery. Its core model integrates electronic medical records (EMRs), telehealth interactions and laboratory testing to generate feedback loops that enable more personalized treatment pathways.
HIMS’ expansion into initiatives like Labs underscores this shift, with offerings designed to track key health markers over time and translate them into doctor-developed action plans. This reflects a broader push toward a more proactive, data-driven healthcare experience, where insights gathered across the platform guide ongoing clinical decisions and deepen patient engagement.
Recent developments further reinforce this data-centric approach. The launch of multi-cancer early detection testing connects users to advanced screening technologies capable of identifying signals across numerous conditions, expanding the platform’s diagnostic depth. At the same time, partnerships and collaborations — such as the integration of advanced diagnostics through wellness benefits and access to a broader range of approved therapies — are designed to enhance the volume and quality of health data flowing through the ecosystem.
Strategic acquisitions and global expansion efforts add another layer to this data strategy. By incorporating technologies like advanced blood sampling and scaling into new geographies through acquisitions, Hims & Hers is extending its ability to capture and utilize health data across broader populations. This growing repository of insights not only supports more tailored care but also strengthens the platform’s ability to continuously refine treatment pathways, reinforcing data as a central pillar of its long-term model.
Tempus AI, Inc. (TEM - Free Report) is fundamentally built on large-scale, proprietary datasets, with the company integrating clinical, molecular and real-world patient data into a unified platform that powers its AI-driven diagnostics. TEM leverages one of the industry’s most expansive multimodal data libraries to train models and generate patient-specific insights, while it continues expanding its capabilities through acquisitions like Ambry Genetics to broaden its data footprint across diseases. By structuring and harmonizing vast healthcare data streams, Tempus AI enables more precise, data-driven treatment decisions at scale.
Doximity, Inc.’s (DOCS - Free Report) model is deeply rooted in leveraging large-scale, proprietary datasets, with Doximity building a vast, interactive database that combines member-generated information with previously siloed public data to generate unique insights for healthcare stakeholders. Doximity continuously refines this data through ongoing platform interactions, enabling personalized content, targeted engagement and AI-driven solutions. More recently, DOCS has strengthened its data advantage through acquisitions like Pathway, adding one of the largest structured clinical datasets purpose-built for AI, further enhancing its expanding suite of data-powered clinical tools.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 4.5% year to date, outperforming the industry’s decline of 18.3%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.4X is lower than the industry’s average of 3.5X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 15.1% improvement compared with 2025.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Builds Scalable Data-Driven Personalized Care Platform
Key Takeaways
Hims & Hers Health, Inc. (HIMS - Free Report) has increasingly positioned itself at the intersection of healthcare and data, building a platform where insights derived from continuous monitoring, diagnostics and user engagement inform care delivery. Its core model integrates electronic medical records (EMRs), telehealth interactions and laboratory testing to generate feedback loops that enable more personalized treatment pathways.
HIMS’ expansion into initiatives like Labs underscores this shift, with offerings designed to track key health markers over time and translate them into doctor-developed action plans. This reflects a broader push toward a more proactive, data-driven healthcare experience, where insights gathered across the platform guide ongoing clinical decisions and deepen patient engagement.
Recent developments further reinforce this data-centric approach. The launch of multi-cancer early detection testing connects users to advanced screening technologies capable of identifying signals across numerous conditions, expanding the platform’s diagnostic depth. At the same time, partnerships and collaborations — such as the integration of advanced diagnostics through wellness benefits and access to a broader range of approved therapies — are designed to enhance the volume and quality of health data flowing through the ecosystem.
Strategic acquisitions and global expansion efforts add another layer to this data strategy. By incorporating technologies like advanced blood sampling and scaling into new geographies through acquisitions, Hims & Hers is extending its ability to capture and utilize health data across broader populations. This growing repository of insights not only supports more tailored care but also strengthens the platform’s ability to continuously refine treatment pathways, reinforcing data as a central pillar of its long-term model.
Hims & Hers is scheduled to report first-quarter 2026 results on May 11, after the closing bell.
TEM & DOCS’ Data Driven Healthcare Platforms
Tempus AI, Inc. (TEM - Free Report) is fundamentally built on large-scale, proprietary datasets, with the company integrating clinical, molecular and real-world patient data into a unified platform that powers its AI-driven diagnostics. TEM leverages one of the industry’s most expansive multimodal data libraries to train models and generate patient-specific insights, while it continues expanding its capabilities through acquisitions like Ambry Genetics to broaden its data footprint across diseases. By structuring and harmonizing vast healthcare data streams, Tempus AI enables more precise, data-driven treatment decisions at scale.
Doximity, Inc.’s (DOCS - Free Report) model is deeply rooted in leveraging large-scale, proprietary datasets, with Doximity building a vast, interactive database that combines member-generated information with previously siloed public data to generate unique insights for healthcare stakeholders. Doximity continuously refines this data through ongoing platform interactions, enabling personalized content, targeted engagement and AI-driven solutions. More recently, DOCS has strengthened its data advantage through acquisitions like Pathway, adding one of the largest structured clinical datasets purpose-built for AI, further enhancing its expanding suite of data-powered clinical tools.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 4.5% year to date, outperforming the industry’s decline of 18.3%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.4X is lower than the industry’s average of 3.5X and its five-year median of 2.6X. It has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2026 earnings per share suggests a 15.1% improvement compared with 2025.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.